On the basis of these data, we proposed that chemotherapy combined with HDAC inhibitors might represent a valuable therapeutic option to produce robust and durable benefit for ovarian cancer patients featured by PAX8 dependency. This evidence concerns the gene HDAC9 and ovarian carcinoma.